Articles by The Wall Street Analyzer

About The Wall Street Analyzer
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.
News Feed

Late-Breaking ACQFORCE FLUTTER Trial Meets Primary Endpoint for Safety and Efficacy with the First Gold-Tipped Contact Force Sensing Ablation Catheter

February 6, 2023 The Wall Street Analyzer Comments Off on Late-Breaking ACQFORCE FLUTTER Trial Meets Primary Endpoint for Safety and Efficacy with the First Gold-Tipped Contact Force Sensing Ablation Catheter

The AcQBlate Force Sensing Ablation Catheter and System demonstrated 94% acute success with no serious adverse events and significantly less ablation time […]

News Feed

XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

February 2, 2023 The Wall Street Analyzer Comments Off on XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat […]